Last reviewed · How we verify
Selexipag matrix tablet
At a glance
| Generic name | Selexipag matrix tablet |
|---|---|
| Also known as | JNJ-67896049 |
| Sponsor | Actelion |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selexipag matrix tablet CI brief — competitive landscape report
- Selexipag matrix tablet updates RSS · CI watch RSS
- Actelion portfolio CI